^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LAG3 expression

    i
    Other names: LAG3, Lymphocyte Activating 3, Lymphocyte Activation Gene 3 Protein, Lymphocyte-Activation Gene 3, CD223 Antigen, CD223, LAG-3, FDC
    Entrez ID:
    3902
    Related biomarkers:
    Expression
    Mutation
    Others
    1d
    Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis. (PubMed, Elife)
    In ICI-ILD, we found an increase in CD57+ CD8+ T cells expressing immune checkpoints (TIGIT+ LAG3+ TIM-3+ PD-1+), FCRL5+ B cells, and CCR2+ CCR5+ CD14+ monocytes. These findings uncover the diverse immunophenotypes and possible pathomechanisms of cancer treatment-related pneumonitis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD14 (CD14 Molecule) • CCR2 (C-C Motif Chemokine Receptor 2) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
    |
    CD8 expression • LAG3 expression • HAVCR2 expression
    2d
    Unraveling the Heterogeneity of CD8+ T-Cell Subsets in Liver Cirrhosis: Implications for Disease Progression. (PubMed, Gut Liver)
    : In summary, this comprehensive study defines specialized CD8+ T-cell subpopulations in cirrhosis, with CXCL13+ Tex cells displaying an exhausted phenotype associated with immune dysregulation and advanced disease. Key genes and pathways regulating these cells present potential therapeutic targets.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    LAG3 expression • CXCL13 expression
    5d
    Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status (PubMed, Arkh Patol)
    A study using multiplex immunohistochemical analysis showed that MMR-deficient colon adenocarcinomas are characterized by more pronounced immune infiltration and increased expression of immune checkpoints in microenvironmental cells, mainly in the area of invasive tumor growth. The data obtained may be important for understanding the mechanisms of immune-mediated control of tumor growth and the choice of immunotherapy tactics depending on MMR status.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1) • LAG3 (Lymphocyte Activating 3) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • CD163 (CD163 Molecule)
    |
    PD-L1 expression • MSI-H/dMMR • LAG3 expression • CTLA4 expression
    7d
    Single-cell RNA sequencing explores the evolution of the ecosystem from leukoplakia to head and neck squamous cell carcinoma. (PubMed, Sci Rep)
    Tumor-promoting genes such as CD163 and CD209 were highly expressed in the myeloid cells, and depletion marker genes such as TIGIT, LAG3 were highly expressed in NK/T cells. Our study may provide a reference for the molecular mechanism of HNSCC and theoretical basis for the development of new therapeutic strategies.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CD163 (CD163 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • AURKB (Aurora Kinase B) • SFRP1 (Secreted frizzled related protein 1) • CD1C (CD1c Molecule)
    |
    LAG3 expression
    8d
    Development and validation of a pyroptosis-related prognostic signature associated with osteosarcoma metastasis and immune infiltration. (PubMed, Medicine (Baltimore))
    In this study, a prognostic model was constructed based on 8 PRGs were proved to be independent prognostic factors of OS and associated with tumor immune microenvironment. These 8 prognostic genes were involved in OS development and may serve as new targets for developing therapeutic drugs.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • IL2RA (Interleukin 2 receptor, alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD5 (CD5 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • ITGAM (Integrin, alpha M) • TLR4 (Toll Like Receptor 4) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    LAG3 expression
    9d
    Inhibition of USP7 enhances CD8+ T cell activity in liver cancer by suppressing PRDM1-mediated FGL1 upregulation. (PubMed, Acta Pharmacol Sin)
    We showed that knockdown of USP7 or treatment with USP7 inhibitor P5091 suppressed liver cancer growth by promoting CD8+ T cell activity in Hepa1-6 xenograft mice and in HepG2 or Huh7 cells co-cultured with T cells, whereas USP7 overexpression produced the opposite effect...In an immunocompetent liver cancer mouse model, the dual blockade of USP7 and LAG3 resulted in a superior antitumor activity compared with anti-LAG3 therapy alone. We conclude that USP7 diminishes CD8+ T cell activity by a USP7/PRDM1 positive feedback loop on FGL1 production in liver cancer; USP7 might be a promising target for liver cancer immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PRDM1 (PR/SET Domain 1) • FGL1 (Fibrinogen Like 1) • USP7 (Ubiquitin Specific Peptidase 7)
    |
    CD8 expression • LAG3 expression
    |
    P5091
    22d
    Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. (PubMed, J Immunother Cancer)
    Our proteomic analysis reveals an intra-tumoral population of SMA+CAFs enriched in pure DM. Additionally, increased expressions of immune checkpoints (LAG-3 and PD-1) in LA and within tumor were associated with poorer prognosis. These findings might have therapeutic implications and help guide treatment selection in addition to informing potential prognostic significance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD163 (CD163 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule)
    |
    LAG3 expression • CTLA4 expression
    29d
    Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. (PubMed, Nat Med)
    Our findings provide insights into the safety profile of combined PD-1 and LAG-3 blockade in gastroesophageal cancer and highlight the potential of ctDNA analysis to dynamically assess systemic tumor burden during neoadjuvant ICI that may open a therapeutic window for future intervention. ClinicalTrials.gov registration: NCT03044613 .
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
    |
    PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
    |
    PD-L1 expression • LAG3 expression
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    1m
    CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude. (PubMed, J Transl Med)
    In summary, GCs impacted phenotype and function of untransduced and CAR T cell with different magnitude. The nature of the CAR costimulatory domain influenced the magnitude of CAR T cell response to GCs.
    Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • MSLN (Mesothelin) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • LAMP1 (Lysosomal Associated Membrane Protein 1)
    |
    PD-1 expression • LAG3 expression • HAVCR2 expression
    1m
    Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy. (PubMed, Acta Pharm Sin B)
    More importantly, LFOP combined with radiotherapy significantly improve the T cell infiltration in tumor and elevate systemic antitumor immune response. In conclusion, we developed a novel peptide blocking LAG-3/FGL1 which can restore T cell function, and the bispecific peptide synergizes with radiotherapy to further enhance the antitumor immune response.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • FGL1 (Fibrinogen Like 1)
    |
    LAG3 expression
    1m
    Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms. (PubMed, Cancer Invest)
    A low-to-intermediate positive correlation was observed between PD-L1 and TIM-3 expressions (rho: 0.333, p < 0.01). Although PD-L1 expression was higher in grade 3 NET/NEC, MSI status was prominent in grade 1/2 NET.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TNFSF4 (TNF Superfamily Member 4)
    |
    PD-L1 expression • PD-L1 overexpression • LAG3 expression • HAVCR2 expression
    1m
    Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice. (PubMed, J Gastrointest Oncol)
    This study may provide a new therapeutic approach for CRLM. Further clinical study is needed.
    Preclinical • Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • MSLN (Mesothelin) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • GZMB (Granzyme B)
    |
    LAG3 expression • HAVCR2 expression
    1m
    Upregulation of HLA-II related to LAG-3+ CD4+ T cell infiltration is associated with patient outcome in human glioblastoma. (PubMed, Cancer Sci)
    In summary, T cell-tumor cell interactions, such as LAG-3-HLA-II, could confer an immunosuppressive environment in human GBM, leading to poor prognosis in patients. Therefore, targeting the LAG-3-HLA-II interaction could be beneficial in ICI immunotherapy to improve the clinical outcome of GBM patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CD68 (CD68 Molecule)
    |
    LAG3 expression
    1m
    Intratumoral injection of interferon gamma promotes the efficacy anti-PD1 treatment in colorectal cancer. (PubMed, Cancer Lett)
    Additionally, PD1 induced increased lymphocyte activating 3 (LAG3) expression in a significant fraction of CD8+ T cells and Treg cells, indicating potential drug resistance and feedback mechanisms. In conclusion, our work provides preclinical data for the Combined immunotherapy of CRC using intratumoral delivery of IFNγ and systemic anti-PD1 monoclonoal antibody.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression
    1m
    Phenotypic and functional exhaustion of circulating CD3+ CD56+ NKT-like cells in colorectal cancer patients. (PubMed, FASEB J)
    Altogether, this research revealed that circulating NKT-like cells in CRC patients exhibited suppressive phenotype and functional impairment, which was more pronounced in NKG2A+ NKT-like cells. These findings suggest that NKG2A blockade may restore anti-tumor effector function in NKT-like cells, which provides a potential target for immunotherapy in CRC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • NCAM1 (Neural cell adhesion molecule 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    LAG3 expression
    1m
    Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2023 --> Jun 2024
    Trial completion date • IO biomarker
    |
    AR (Androgen receptor) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CD276 (CD276 Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TNFRSF9 (TNF Receptor Superfamily Member 9) • LAMP1 (Lysosomal Associated Membrane Protein 1)
    |
    CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression
    |
    enoblituzumab (MGA271)
    2ms
    LAG-3- and CXCR5-expressing CD4 T cells display progenitor-like properties during chronic visceral leishmaniasis. (PubMed, Cell Rep)
    The transcriptional repressor B cell lymphoma-6 was partially required for their maintenance. Altogether, we propose that the LAG3+CXCR5+ CD4 T cell subset could play a role in maintaining CD4 T cell responses during persistent infections.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • RAG1 (Recombination Activating 1)
    |
    LAG3 expression • CD4 expression • CXCR5 expression
    2ms
    A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients (clinicaltrials.gov)
    P2, N=132, Recruiting, Shanghai Henlius Biotech | N=60 --> 132
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • LAG3 (Lymphocyte Activating 3)
    |
    PD-L1 expression • ROS1 rearrangement • LAG3 expression
    |
    carboplatin • albumin-bound paclitaxel • Hansizhuang (serplulimab) • HLX26
    2ms
    Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment. (PubMed, Cell Rep)
    TFH-like cytotoxic CD4+ T cells have high LAG-3/BLIMP1 and low TCF1 expression without self-renewal ability, whereas non-cytotoxic TFH cells express low LAG-3/BLIMP1 and high TCF1 with self-renewal ability, closely resembling the relationship between terminally differentiated and stem-like progenitor exhaustion in CD8+ T cells, respectively. Our findings provide deep insights into TFH-like CD4+ T cell exhaustion with helper progenitor and cytotoxic differentiated functions, mediating anti-tumor immunity orchestrally with CD8+ T cells.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • PRDM1 (PR/SET Domain 1)
    |
    LAG3 expression • CXCL13 expression
    2ms
    LAG3 Expression in Triple Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=128, Recruiting, Samsung Medical Center
    New trial • Checkpoint inhibition • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression
    2ms
    Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade. (PubMed, Cancer Immunol Immunother)
    Further, LAG-3 expression was found to be increased within the TME following intratumoral CPMV administration. The integration of CPMV IIT with LAG-3 inhibition holds significant potential to improve treatment outcomes by concurrently inducing a comprehensive anti-tumor immune response, enhancing local immune activation, and mitigating T cell exhaustion.
    Journal • Combination therapy • Checkpoint inhibition • IO biomarker • Checkpoint block
    |
    LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression
    2ms
    TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer. (PubMed, Eur J Med Res)
    A combined hypoxia and immune-related gene could be a novel predictive model for OS and immunotherapy estimation of BLCA patients and TFRC could be used as a potential therapeutic target in the future.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    LAG3 expression
    2ms
    Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade. (PubMed, Sci Rep)
    The role of LAG-3 expression on circulating NK cells, as well as the expression of LAG-3 ligands on tumor cells and the early modulation of circulating cytotoxic CD4+ T cells warrant further investigation as exploitable predictive biomarkers for dual PD-1 and LAG-3 blockade.Trial registration: NCT02460224. Registered 02/06/2015.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • GZMB (Granzyme B)
    |
    PD-L1 negative • LAG3 expression
    2ms
    Tumor-infiltrating γδ T cells as targets of immune checkpoint blockade in melanoma. (PubMed, J Leukoc Biol)
    Lastly, a correlation analysis between γδ T cell abundance, immune checkpoint gene expression, and clinical outcomes in melanoma patients showed that low expression of immune checkpoint genes, including LAG3, HAVCR2, and PDCD1, was associated with improved 1-year overall survival, emphasizing the significance of these genes in predicting patient outcomes, potentially outweighing the impact of γδ T cell abundance. This study offers critical insights into the dynamic interaction between γδ T cells, immune checkpoint receptors, and melanoma, providing valuable prospectives for potential therapeutic avenues and predictive markers in this intricate interplay.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    PD-1 expression • LAG3 expression
    2ms
    LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes. (PubMed, Am J Cancer Res)
    Taken together, these results suggest that high LAG-3 levels in and of themselves do not predict resistance to anti-PD-1/PD-L1 checkpoint blockade. Even so, since LAG-3 is often co-expressed with PD-1, PD-L1 and/or CTLA-4, selecting patients for combinations of checkpoint blockade based on immunomic co-expression patterns is a strategy that merits exploration.
    Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • LAG3 expression
    2ms
    Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Dan Zandberg | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    LAG3 expression • CTLA4 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    3ms
    Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic. (PubMed, Pathol Res Pract)
    The realization of LAG-3's promise necessitates global collaboration and equal access. Multinational trials are expected to ascertain the efficacy of the intervention in various patient groups.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule)
    |
    LAG3 expression
    3ms
    Astragalus polysaccharide ameliorates CD8 T cell dysfunction through STAT3/Gal-3/LAG3 pathway in inflammation-induced colorectal cancer. (PubMed, Biomed Pharmacother)
    Co-culture experiments with MC38 and CD8 T cells demonstrated that APS decreased the expression of co-inhibitory receptor LAG3 in CD8 T cells by targeting STAT3/Gal-3 in MC38 cells. Mechanism investigations revealed that APS specifically improved CD8 T cell function through modulation of the STAT3/Gal-3/LAG3 pathway to inhibit CRC development, providing insights for future clinical development of natural anti-tumor drugs and immunotherapies as a novel strategy combined with immune checkpoint inhibitors (ICIs).
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • LGALS3 (Galectin 3)
    |
    LAG3 expression
    3ms
    Integrative analysis of LAG3 immune signature and identification of a LAG3-related genes prognostic signature in kidney renal clear cell carcinoma. (PubMed, Aging (Albany NY))
    In conclusion, our study implies that LAG3 can serve as a potential prognostic biomarker for KIRC. Furthermore, blocking both LAG3 and PDCD1 may alleviate resistance to anti-PDCD1 therapy, providing novel insights for immunotherapy decision-making in KIRC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
    |
    CD8 expression • LAG3 expression
    3ms
    Epidermolysis-Bullosa-Associated Squamous Cell Carcinomas Support an Immunosuppressive Tumor Microenvironment: Prospects for Immunotherapy. (PubMed, Cancers (Basel))
    KEB-SCCs showed the lowest expression of the exhaustion markers TIM-3 and LAG-3 compared with all other groups. These findings identify IDO, PD-1, and PD-L1 to be increased in EB-SCCs and candidate targets for combinatory treatments, especially in DEB-SCCs.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)
    |
    LAG3 expression • HAVCR2 expression • IDO1 expression • CD4 positive
    3ms
    Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach. (PubMed, Biomedicines)
    In addition, we will discuss what will be the future implementation of these strategies against cancer drug resistance. Finally, we will emphasize the practical steps to lay the groundwork for enlightened policy for intervention and resource allocation to care for cancer patients.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    |
    LAG3 expression • HAVCR2 expression
    3ms
    Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. (PubMed, Int J Mol Sci)
    In conclusion, the CD8sp_41BBz STEAP1 CAR T cells had superior expansion and survival in vitro and in vivo, compared to the IgGsp_CD28z counterpart, and a less exhausted phenotype upon repeated antigen exposure. Such persistence may be important for clinical efficacy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • STEAP1 (STEAP Family Member 1) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    PD-1 expression • LAG3 expression • STEAP1 expression
    3ms
    The Involvement of LAG-3 Plasma Cells in the Development of Multiple Myeloma. (PubMed, Int J Mol Sci)
    Grz expression was significantly decreased in CD8T cells incubated with CD138LAG-3 PCs, compared to CD138LAG-3 PCs in patients with plasma cell dyscrasia, n = 31, p = 0.0041. LAG-3 expression on malignant PCs can be involved in the development of MM from MGUS by decreasing the expression of Grz in CD8T cells.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • SDC1 (Syndecan 1)
    |
    CD8 expression • LAG3 expression
    3ms
    Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1. (PubMed, Int J Cancer)
    In addition, SKM-BBz CAR-T cells showed upregulation of early memory markers, such as TCF7 and CCR7, as well as downregulation of pro-apoptotic proteins, such as BAK1 and BID, which may be associated with phenotypical and functional differences between SKM-BBz and SKM-28z CAR-T cells. In conclusion, we developed novel SKM9-2-derived CAR-T cells with the 4-1BB costimulatory domain, which could provide a promising therapeutic approach against refractory MM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CCR7 (Chemokine (C-C motif) receptor 7) • BAK1 (BCL2 Antagonist/Killer 1) • HEG1 (Heart Development Protein With EGF Like Domains 1) • TCF7 (Transcription Factor 7)
    |
    PD-1 expression • LAG3 expression
    3ms
    CD8 + T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia. (PubMed, Inflamm Res)
    Our results suggest that the molecular subtypes we constructed have potential application value in the prognosis evaluation and treatment guidance of AML patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    FLT3 mutation • LAG3 expression
    3ms
    Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis. (PubMed, Laryngoscope)
    Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Laryngoscope, 2024.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • FLT4 (Fms-related tyrosine kinase 4) • LGALS9 (Galectin 9)
    |
    PD-L1 expression • PD-1 expression • CD8 expression • LAG3 expression • HAVCR2 expression • KDR expression • PD-1 elevation • TIGIT expression • PD-L2 expression
    4ms
    A combined analysis of multi-omics data reveals the prognostic values and immunotherapy response of LAG3 in human cancers. (PubMed, Eur J Med Res)
    We also examined the distribution of LAG3 at the single-cell level and explored its functional significance. A comprehensive and systematic analysis of LAG3 would facilitate a comprehensive evaluation of LAG3 in cancer biology and provide valuable insights for cancer management.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression • LAG3 elevation
    4ms
    Comprehensive analysis of single-cell and bulk RNA-sequencing data identifies B cell marker genes signature that predicts prognosis and analysis of immune checkpoints expression in head and neck squamous cell carcinoma. (PubMed, Heliyon)
    However, there was no statistically significant difference between PD-L1, PD-L2, CTLA-4, TIGIT and prognosis. The BCMGS was a promising prognostic biomarker in HNSC, which may help to interpret the responses to immunotherapy and provide a new perspective for future research on the treatment in HNSC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • FTH1 (Ferritin Heavy Chain 1)
    |
    LAG3 expression • HAVCR2 expression
    4ms
    Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade. (PubMed, J Immunother Cancer)
    Additionally, we present a patient with locally-advanced BCC who experienced stable disease during and after 45 weeks of first-line anti-PD-1 (nivolumab), followed by a partial response after the addition of anti-LAG-3 (relatlimab). Longitudinal biopsies throughout the treatment course showed a graduated increase in LAG-3 expression after anti-PD-1 therapy, lending support for coordinated immunosuppression and suggesting LAG-3 as a co-target for combination therapy to augment the clinical impact of anti-PD-(L)1.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    PD-L1 expression • LAG3 expression
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    4ms
    Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapy. (PubMed, PLoS One)
    The study also found that Tregs had a dense communication network with cluster two, and that certain ligand-receptor pairs, including SPP1/CD44, HLA-E/KLRC2, HLA-E/KLRK1, ANXA1/FPR3, and CXCL9/FCGR2A, had notable changes after the therapy. These changes in gene expression and cell interactions may have implications for the role of Tregs in the TME and in response to Nivolumab therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • LAG3 (Lymphocyte Activating 3) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • LY9 (Lymphocyte Antigen 9) • ANXA1 (Annexin A1) • HLA-E (Major Histocompatibility Complex, Class I, E) • FCGR2A (Fc fragment of IgG receptor IIa) • FOXP3 (Forkhead Box P3) • GZMA (Granzyme A) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • FPR3 (Formyl Peptide Receptor 3) • KLRC2 (Killer Cell Lectin Like Receptor C2) • NKG2D (killer cell lectin like receptor K1)
    |
    PD-1 expression • LAG3 expression • CTLA4 expression
    |
    Opdivo (nivolumab)
    4ms
    Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma. (PubMed, Appl Immunohistochem Mol Morphol)
    The patients' poor prognosis may be related to the immunohistochemistry expression of LAG-3, Tim-3, and CTLA-4 in CRC cancer tissue and TILs. Poor patient consequences can result from the CTLA-4, Tim-3, and LAG-3 co-expression, but CTLA-4 TILs' expression of these proteins may inhibit the growth of tumors.
    Journal • Tumor-infiltrating lymphocyte • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    LAG3 expression • HAVCR2 expression • CTLA4 expression
    4ms
    Prognostic value and immunological role of cathepsin S gene in pan‑cancer. (PubMed, Oncol Lett)
    Functional enrichment analysis suggested that CTSS could drive a dynamic adjustment of biological functions and pathways in BLCA, SKCM, LGG and UVM, including immune response regulating signaling pathways, regulation of lymphocyte activation and T cell receptor singling pathways. The current study suggested that CTSS could be an essential biomarker for prognosis and immune infiltration features in multiple cancers.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • CTSS (Cathepsin S)
    |
    LAG3 expression • CTSS overexpression